A novel pharmacological mechanism of anti-cancer drugs that induce pyroptosis
Inflammopharmacology. 2023 Mar 3. doi: 10.1007/s10787-023-01148-6. Online ahead of print.ABSTRACTPyroptosis is an inflammasome-induced lytic form of programmed cell death, and its main effect involves the release of inflammatory mediators when a cell dies, resulting in an inflammatory response in the body. The key to pyroptosis is the cleavage of GSDMD or other gasdermin families. Some drugs can cause cleavage GSDMD or other gasdermin members cause pyroptosis and suppress cancer growth and development. This review explores several drugs that may induce pyroptosis, thereby contributing to tumor treatment. Pyroptosis-inducin...
Source: Cancer Control - March 3, 2023 Category: Cancer & Oncology Authors: Haohao Guo Ziyang Wang Runsheng Ma Xin Chen Hongqiang Li Yifeng Tang Gongbo Du Yifei Zhang Detao Yin Source Type: research
A novel pharmacological mechanism of anti-cancer drugs that induce pyroptosis
AbstractPyroptosis is an inflammasome-induced lytic form of programmed cell death, and its main effect involves the release of inflammatory mediators when a cell dies, resulting in an inflammatory response in the body. The key to pyroptosis is the cleavage of GSDMD or other gasdermin families. Some drugs can cause cleavage GSDMD or other gasdermin members cause pyroptosis and suppress cancer growth and development. This review explores several drugs that may induce pyroptosis, thereby contributing to tumor treatment. Pyroptosis-inducing drugs, such as arsenic, platinum, and doxorubicin, were used originally in cancer treat...
Source: Inflammopharmacology - March 3, 2023 Category: Drugs & Pharmacology Source Type: research
Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs
Chem Pharm Bull (Tokyo). 2023;71(3):213-219. doi: 10.1248/cpb.c22-00685.ABSTRACTThe purpose of the present study was to provide the experimental and theoretical basis of bioequivalence (BE) dissolution test criteria for formulation development of high solubility-low permeability drugs. According to the biowaiver scheme based on the biopharmaceutics classification system (BCS), for BCS class III drugs, a test formulation and a reference formulation are predicted to be BE when 85% of the drug dissolves within 15 min (T85% < 15 min) in the compendial dissolution test. However, previous theoretical simulation studies have s...
Source: Chemical and Pharmaceutical Bulletin - March 1, 2023 Category: Drugs & Pharmacology Authors: Asami Ono Rena Kurihara Katsuhide Terada Kiyohiko Sugano Source Type: research
Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs
Chem Pharm Bull (Tokyo). 2023;71(3):213-219. doi: 10.1248/cpb.c22-00685.ABSTRACTThe purpose of the present study was to provide the experimental and theoretical basis of bioequivalence (BE) dissolution test criteria for formulation development of high solubility-low permeability drugs. According to the biowaiver scheme based on the biopharmaceutics classification system (BCS), for BCS class III drugs, a test formulation and a reference formulation are predicted to be BE when 85% of the drug dissolves within 15 min (T85% < 15 min) in the compendial dissolution test. However, previous theoretical simulation studies have s...
Source: Chemical and Pharmaceutical Bulletin - March 1, 2023 Category: Drugs & Pharmacology Authors: Asami Ono Rena Kurihara Katsuhide Terada Kiyohiko Sugano Source Type: research
Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs
Chem Pharm Bull (Tokyo). 2023;71(3):213-219. doi: 10.1248/cpb.c22-00685.ABSTRACTThe purpose of the present study was to provide the experimental and theoretical basis of bioequivalence (BE) dissolution test criteria for formulation development of high solubility-low permeability drugs. According to the biowaiver scheme based on the biopharmaceutics classification system (BCS), for BCS class III drugs, a test formulation and a reference formulation are predicted to be BE when 85% of the drug dissolves within 15 min (T85% < 15 min) in the compendial dissolution test. However, previous theoretical simulation studies have s...
Source: Chemical and Pharmaceutical Bulletin - March 1, 2023 Category: Drugs & Pharmacology Authors: Asami Ono Rena Kurihara Katsuhide Terada Kiyohiko Sugano Source Type: research
Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs
Chem Pharm Bull (Tokyo). 2023;71(3):213-219. doi: 10.1248/cpb.c22-00685.ABSTRACTThe purpose of the present study was to provide the experimental and theoretical basis of bioequivalence (BE) dissolution test criteria for formulation development of high solubility-low permeability drugs. According to the biowaiver scheme based on the biopharmaceutics classification system (BCS), for BCS class III drugs, a test formulation and a reference formulation are predicted to be BE when 85% of the drug dissolves within 15 min (T85% < 15 min) in the compendial dissolution test. However, previous theoretical simulation studies have s...
Source: Chemical and Pharmaceutical Bulletin - March 1, 2023 Category: Drugs & Pharmacology Authors: Asami Ono Rena Kurihara Katsuhide Terada Kiyohiko Sugano Source Type: research
Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs
Chem Pharm Bull (Tokyo). 2023;71(3):213-219. doi: 10.1248/cpb.c22-00685.ABSTRACTThe purpose of the present study was to provide the experimental and theoretical basis of bioequivalence (BE) dissolution test criteria for formulation development of high solubility-low permeability drugs. According to the biowaiver scheme based on the biopharmaceutics classification system (BCS), for BCS class III drugs, a test formulation and a reference formulation are predicted to be BE when 85% of the drug dissolves within 15 min (T85% < 15 min) in the compendial dissolution test. However, previous theoretical simulation studies have s...
Source: Chemical and Pharmaceutical Bulletin - March 1, 2023 Category: Drugs & Pharmacology Authors: Asami Ono Rena Kurihara Katsuhide Terada Kiyohiko Sugano Source Type: research
Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs
Chem Pharm Bull (Tokyo). 2023;71(3):213-219. doi: 10.1248/cpb.c22-00685.ABSTRACTThe purpose of the present study was to provide the experimental and theoretical basis of bioequivalence (BE) dissolution test criteria for formulation development of high solubility-low permeability drugs. According to the biowaiver scheme based on the biopharmaceutics classification system (BCS), for BCS class III drugs, a test formulation and a reference formulation are predicted to be BE when 85% of the drug dissolves within 15 min (T85% < 15 min) in the compendial dissolution test. However, previous theoretical simulation studies have s...
Source: Chemical and Pharmaceutical Bulletin - March 1, 2023 Category: Drugs & Pharmacology Authors: Asami Ono Rena Kurihara Katsuhide Terada Kiyohiko Sugano Source Type: research
Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs
Chem Pharm Bull (Tokyo). 2023;71(3):213-219. doi: 10.1248/cpb.c22-00685.ABSTRACTThe purpose of the present study was to provide the experimental and theoretical basis of bioequivalence (BE) dissolution test criteria for formulation development of high solubility-low permeability drugs. According to the biowaiver scheme based on the biopharmaceutics classification system (BCS), for BCS class III drugs, a test formulation and a reference formulation are predicted to be BE when 85% of the drug dissolves within 15 min (T85% < 15 min) in the compendial dissolution test. However, previous theoretical simulation studies have s...
Source: Chemical and Pharmaceutical Bulletin - March 1, 2023 Category: Drugs & Pharmacology Authors: Asami Ono Rena Kurihara Katsuhide Terada Kiyohiko Sugano Source Type: research
Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs
Chem Pharm Bull (Tokyo). 2023;71(3):213-219. doi: 10.1248/cpb.c22-00685.ABSTRACTThe purpose of the present study was to provide the experimental and theoretical basis of bioequivalence (BE) dissolution test criteria for formulation development of high solubility-low permeability drugs. According to the biowaiver scheme based on the biopharmaceutics classification system (BCS), for BCS class III drugs, a test formulation and a reference formulation are predicted to be BE when 85% of the drug dissolves within 15 min (T85% < 15 min) in the compendial dissolution test. However, previous theoretical simulation studies have s...
Source: Chemical and Pharmaceutical Bulletin - March 1, 2023 Category: Drugs & Pharmacology Authors: Asami Ono Rena Kurihara Katsuhide Terada Kiyohiko Sugano Source Type: research
Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs
Chem Pharm Bull (Tokyo). 2023;71(3):213-219. doi: 10.1248/cpb.c22-00685.ABSTRACTThe purpose of the present study was to provide the experimental and theoretical basis of bioequivalence (BE) dissolution test criteria for formulation development of high solubility-low permeability drugs. According to the biowaiver scheme based on the biopharmaceutics classification system (BCS), for BCS class III drugs, a test formulation and a reference formulation are predicted to be BE when 85% of the drug dissolves within 15 min (T85% < 15 min) in the compendial dissolution test. However, previous theoretical simulation studies have s...
Source: Chemical and Pharmaceutical Bulletin - March 1, 2023 Category: Drugs & Pharmacology Authors: Asami Ono Rena Kurihara Katsuhide Terada Kiyohiko Sugano Source Type: research
Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs
Chem Pharm Bull (Tokyo). 2023;71(3):213-219. doi: 10.1248/cpb.c22-00685.ABSTRACTThe purpose of the present study was to provide the experimental and theoretical basis of bioequivalence (BE) dissolution test criteria for formulation development of high solubility-low permeability drugs. According to the biowaiver scheme based on the biopharmaceutics classification system (BCS), for BCS class III drugs, a test formulation and a reference formulation are predicted to be BE when 85% of the drug dissolves within 15 min (T85% < 15 min) in the compendial dissolution test. However, previous theoretical simulation studies have s...
Source: Chemical and Pharmaceutical Bulletin - March 1, 2023 Category: Drugs & Pharmacology Authors: Asami Ono Rena Kurihara Katsuhide Terada Kiyohiko Sugano Source Type: research
